A more recent clinical trial showed that dapaglifozin effectively decreases glucose levels after 12 weeks of treatment in participants with T2DM receiving insulin treatment, even if no effect was observed in glucose variability. This evidence concerns the gene INS and type 2 diabetes mellitus.